Cargando…
PReS-FINAL-2330: Canakinumab treatment in patients with HIDS
Autores principales: | Antón, J, Calvo, I, Robles, A, Yagüe, J, Aróstegui, J, Viana, R, Bhansali, S, Abrams, K |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4044468/ http://dx.doi.org/10.1186/1546-0096-11-S2-P320 |
Ejemplares similares
-
Long-term efficacy and safety of Canakinumab in active Hyper-IgD syndrome (HIDS): results from an open-label study
por: Aróstegui, JI, et al.
Publicado: (2015) -
PReS-FINAL-2224: Canakinumab treatment regimens in CAPS-patients
por: Hofer, F, et al.
Publicado: (2013) -
Hiper IgD syndrome (HIDS): clinical and genetic features in five patients
por: Marco, A, et al.
Publicado: (2008) -
PReS-FINAL-2169: Exposure-response modeling of canakinumab in the avoidance of flares in children with systemic juvenile idiopathic arthritis
por: Xiong, Y, et al.
Publicado: (2013) -
PReS-FINAL-2157: Efficacy of canakinumab in the treatment of systemic juvenile idiopathic arthritis: a 12-week pooled post-hoc analysis
por: Quartier, P, et al.
Publicado: (2013)